Recent studies also support the sustained improvement in cardiovascular risk categories, indicating that SGLT2 inhibitors attenuate left ventricular remodeling and endothelial dysfunction, mechanisms that are critical for cardiovascular risk reduction [21,52]. The gene discussed is SLC5A2; the disease is endothelial dysfunction.